Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.

Vincelette ND, Ding H, Huehls AM, Flatten KS, Kelly RL, Kohorst MA, Webster J, Hess AD, Pratz KW, Karnitz LM, Kaufmann SH.

Sci Rep. 2019 Mar 5;9(1):3617. doi: 10.1038/s41598-019-40218-0.

2.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
3.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.

Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.

Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.

4.

Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis.

Maskey RS, Flatten KS, Sieben CJ, Peterson KL, Baker DJ, Nam HJ, Kim MS, Smyrk TC, Kojima Y, Machida Y, Santiago A, van Deursen JM, Kaufmann SH, Machida YJ.

Nucleic Acids Res. 2017 May 5;45(8):4564-4576. doi: 10.1093/nar/gkx107.

5.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

6.

Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes.

Perkins AL, Peterson KL, Beito TG, Flatten KS, Kaufmann SH, Harki DA.

Org Biomol Chem. 2016 Apr 26;14(17):4103-9. doi: 10.1039/c5ob02049b.

7.

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH.

Clin Cancer Res. 2016 Aug 1;22(15):3894-902. doi: 10.1158/1078-0432.CCR-15-2351. Epub 2016 Mar 15.

8.

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH.

Blood. 2016 Jun 2;127(22):2711-22. doi: 10.1182/blood-2015-02-629485. Epub 2016 Feb 25.

9.

Immunodetection of human topoisomerase I-DNA covalent complexes.

Patel AG, Flatten KS, Peterson KL, Beito TG, Schneider PA, Perkins AL, Harki DA, Kaufmann SH.

Nucleic Acids Res. 2016 Apr 7;44(6):2816-26. doi: 10.1093/nar/gkw109. Epub 2016 Feb 24.

10.

Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.

Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH.

J Biol Chem. 2014 Jul 25;289(30):20543-58.

11.

Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.

Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH.

Mol Pharmacol. 2014 May;85(5):723-34. doi: 10.1124/mol.113.088674. Epub 2014 Feb 25.

12.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R.

Haematologica. 2014 Apr;99(4):688-96. doi: 10.3324/haematol.2013.093187. Epub 2013 Oct 31.

13.

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH.

Haematologica. 2014 Jan;99(1):60-9. doi: 10.3324/haematol.2013.087734. Epub 2013 Aug 30.

14.

ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.

Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.

15.

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH.

Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23.

16.

Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.

Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH.

Clin Cancer Res. 2012 Oct 1;18(19):5364-73. doi: 10.1158/1078-0432.CCR-12-0961. Epub 2012 Aug 6.

17.

Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm.

Lee SH, Meng XW, Flatten KS, Loegering DA, Kaufmann SH.

Cell Death Differ. 2013 Jan;20(1):64-76. doi: 10.1038/cdd.2012.93. Epub 2012 Aug 3.

18.

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH.

Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890. Epub 2012 Jan 30.

19.

Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH.

J Biol Chem. 2012 Feb 3;287(6):4198-210. doi: 10.1074/jbc.M111.296475. Epub 2011 Dec 12.

20.

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

Gupta M, Hendrickson AE, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, Flatten KS, Hess AD, Smith BD, Karp JE, Barr S, Witzig TE, Kaufmann SH.

Blood. 2012 Jan 12;119(2):476-87. doi: 10.1182/blood-2011-04-346601. Epub 2011 Nov 11.

21.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM.

Haematologica. 2011 Nov;96(11):1619-26. doi: 10.3324/haematol.2011.049551. Epub 2011 Jul 26.

22.

Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.

Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.

Cancer Res. 2010 Nov 1;70(21):8642-50. doi: 10.1158/0008-5472.CAN-10-1345. Epub 2010 Sep 14.

23.

Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH.

J Biol Chem. 2010 Jan 8;285(2):888-902. doi: 10.1074/jbc.M109.057638. Epub 2009 Nov 3.

24.

On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.

Gálvez-Peralta M, Hackbarth JS, Flatten KS, Kaufmann SH, Hiasa H, Xing C, Ferguson DM.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4459-62. doi: 10.1016/j.bmcl.2009.05.037. Epub 2009 May 18.

25.

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C.

Clin Cancer Res. 2008 Dec 1;14(23):7900-8. doi: 10.1158/1078-0432.CCR-08-0415.

26.

Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH.

Mol Pharmacol. 2008 Sep;74(3):724-35. doi: 10.1124/mol.108.047787. Epub 2008 May 28.

27.
28.

Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.

Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, Lieberman HB, Chen J, Cliby WA, Kaufmann SH.

Mol Pharmacol. 2005 Dec;68(6):1636-44. Epub 2005 Aug 26.

PMID:
16126823
29.

Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.

Farmer LJ, Zhi L, Jeong S, Lamph WW, Osburn DL, Croston G, Flatten KS, Heyman RA, Nadzan AM.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):261-4.

PMID:
12482435
30.

Identification of the first retinoid X, receptor homodimer antagonist.

Canan Koch SS, Dardashti LJ, Hebert JJ, White SK, Croston GE, Flatten KS, Heyman RA, Nadzan AM.

J Med Chem. 1996 Aug 16;39(17):3229-34. No abstract available.

PMID:
8765503

Supplemental Content

Loading ...
Support Center